Cytosorbents (CTSO)
(Delayed Data from NSDQ)
$0.90 USD
+0.02 (2.28%)
Updated May 31, 2024 04:00 PM ET
After-Market: $0.90 0.00 (-0.01%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Cytosorbents Corporation [CTSO]
Reports for Purchase
Showing records 41 - 60 ( 183 total )
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: COVID ARDS (ECMO) Trial Shows Efficacy
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: COVID ARDS (ECMO) Trial Shows Efficacy
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
Continued Topline Growth; STAR-T on U.S. Ticagrelor Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
COVID Revenues Likely to Rebound; Starting Multiple Clinical Studies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: A Star is Born - Pivotal P3 Trial Begins
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
Record Year Boosted by COVID Sales; Continued Growth Expected in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: The Good Doctor: Cytosorb Approved in Korea
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
A Strong Finish to 2020; We Expect Continued Growth in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: How did CytoSorb Perform in 50 COVID Patients?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: Reports a Strong Quarter, Partly Driven by COVID, $88 Million in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
Continued Sales Growth; Significant Clinical Expansion in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: EU Approval for the PerLife Ex System, which uses PerSorb Cartridge for Solid Organ Transplant
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
Company: Cytosorbents Corporation
Industry: Medical - Products
BUY: Record Revenues - This is Just the Beginning
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Cytosorbents Corporation
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department